Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022

Submitted by amarin on Wed, 07/20/2022 - 12:00
Home
News
Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call…
DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s second quarter 2022 financial results on Wednesday, August 3 rd

NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales

Submitted by amarin on Wed, 07/13/2022 - 12:01
Home
News
NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) …
-- Newly published final guidance by the National Institute for Health and Care Excellence (NICE) in the UK confirms its prior draft recommendation for the use of VAZKEPA ® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at

REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo

Submitted by amarin on Thu, 06/30/2022 - 20:05
Home
News
REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Ch…
-- Sub-Analysis Findings Support Prior Analyses that Eicosapentaenoic Acid (EPA) Level is  The Major Determinant of Benefit in REDUCE-IT -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced an exploratory post hoc
Subscribe to